AUTHOR=Lu Ling , Li Yonghong , Luo Rong , Xu Junhui , Feng Jie , Wang Mingqiang 

TITLE=Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis

JOURNAL=Frontiers in Oncology

VOLUME=10

YEAR=2020

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00632

DOI=10.3389/fonc.2020.00632

ISSN=2234-943X

ABSTRACT=<p><bold>Background:</bold> A series of studies have explored the prognostic value of programmed death-ligand 1 (PD-L1) in patients with endometrial cancer (EC); however, the results are controversial. Therefore, this meta-analysis was performed to estimate the associations between PD-L1 expression and the prognosis and clinicopathological features of EC.</p><p><bold>Methods:</bold> A comprehensive literature search of PubMed, Web of Science, and Embase was conducted up until September 06, 2019. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS) were computed using the random-effects model (REM) or fixed-effects model (FEM). Odds ratios (ORs) and 95% CIs were calculated to evaluate the relationship between PD-L1 and clinicopathological factors.</p><p><bold>Results:</bold> A total of 9 studies with 1,615 patients were included in the meta-analysis. The combined data showed that high expression of PD-L1 was not significantly correlated with OS (HR = 1.20, 95% CI = 0.41–3.52, <italic>p</italic> = 0.737) or PFS (HR = 1.12, 95% CI = 0.50–2.54, <italic>p</italic> = 0.778) in EC. In addition, PD-L1 expression was significantly associated with poor differentiation (OR = 2.82, 95% CI = 1.96–4.06, <italic>P</italic> &lt; 0.001) and advanced stage (OR = 1.71, 95% CI = 1.12–2.60, <italic>p</italic> = 0.013).</p><p><bold>Conclusion:</bold> This meta-analysis suggests that PD-L1 expression is not associated with poor prognosis in patients with EC. However, PD-L1 expression is positively correlated with poor differentiation and advanced tumor stage in EC.</p>